These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 33122230)
1. Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity. Hwang D; Dismuke T; Tikunov A; Rosen EP; Kagel JR; Ramsey JD; Lim C; Zamboni W; Kabanov AV; Gershon TR; Sokolsky-Papkov PhD M Nanomedicine; 2021 Feb; 32():102345. PubMed ID: 33259959 [TBL] [Abstract][Full Text] [Related]
2. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. Robinson GW; Orr BA; Wu G; Gururangan S; Lin T; Qaddoumi I; Packer RJ; Goldman S; Prados MD; Desjardins A; Chintagumpala M; Takebe N; Kaste SC; Rusch M; Allen SJ; Onar-Thomas A; Stewart CF; Fouladi M; Boyett JM; Gilbertson RJ; Curran T; Ellison DW; Gajjar A J Clin Oncol; 2015 Aug; 33(24):2646-54. PubMed ID: 26169613 [TBL] [Abstract][Full Text] [Related]
3. Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects. Kresbach C; Holst L; Schoof M; Leven T; Göbel C; Neyazi S; Tischendorf J; Loose C; Wrzeszcz A; Yorgan T; Rutkowski S; Schüller U Neuro Oncol; 2024 Apr; 26(4):609-622. PubMed ID: 37767814 [TBL] [Abstract][Full Text] [Related]
4. Possible mechanisms and biomarkers of resistance to vismodegib in SHH medulloblastoma. Roesler R; de Farias CB; Brunetto AT; Gregianin L; Jaeger M; Nör C; Thomaz A Neuro Oncol; 2022 Jul; 24(7):1210-1211. PubMed ID: 35552442 [No Abstract] [Full Text] [Related]
5. Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib. Cabezas-Camarero S; García-Barberán V; Pérez-Alfayate R; Gómez Del Pulgar ME; Cabrera-Martin MN; Casado-Fariñas I; Pérez-Segura P Oncologist; 2024 May; 29(5):377-383. PubMed ID: 38438322 [TBL] [Abstract][Full Text] [Related]
6. Radiation-Induced Meningioma in a Case of Medulloblastoma Treated 11 Years Ago-Detected on 68Ga-DOTANOC PET/CT. Dev ID; Puranik AD; Rangarajan V; Gupta T; Purandare NC; Agrawal A; Shah S Clin Nucl Med; 2022 Jan; 47(1):e108-e110. PubMed ID: 34183498 [TBL] [Abstract][Full Text] [Related]
7. P-selectin-targeted nanocarriers induce active crossing of the blood-brain barrier via caveolin-1-dependent transcytosis. Tylawsky DE; Kiguchi H; Vaynshteyn J; Gerwin J; Shah J; Islam T; Boyer JA; Boué DR; Snuderl M; Greenblatt MB; Shamay Y; Raju GP; Heller DA Nat Mater; 2023 Mar; 22(3):391-399. PubMed ID: 36864161 [TBL] [Abstract][Full Text] [Related]
8. Cerebellar mass in a 31-year-old woman. Mulone D; Polati R; Miele E; Patrizi S; Mafficini A; Barresi V Brain Pathol; 2024 Jul; 34(4):e13268. PubMed ID: 38766843 [No Abstract] [Full Text] [Related]
9. Leptomeningeal metastases: how best to assess response. Chamberlain MC Neuro Oncol; 2020 Oct; 22(10):1417-1418. PubMed ID: 32770188 [No Abstract] [Full Text] [Related]
11. The genomic and biological complexity of mixed phenotype acute leukemia. Andrews C; Tierens A; Minden M Crit Rev Clin Lab Sci; 2021 May; 58(3):153-166. PubMed ID: 33161794 [TBL] [Abstract][Full Text] [Related]
12. Citrulline as a biomarker of bacteraemia during induction treatment for childhood acute lymphoblastic leukaemia. De Pietri S; Frandsen TL; Christensen M; Grell K; Rathe M; Müller K Pediatr Blood Cancer; 2021 Jan; 68(1):e28793. PubMed ID: 33155402 [TBL] [Abstract][Full Text] [Related]
13. A Holistic Review on the Current and Future Status of Biology-Driven and Broad-Spectrum Therapeutic Options for Medulloblastoma. Pritha A; Anderson R; Anderson DE; Nicolaides T Cureus; 2022 Mar; 14(3):e23447. PubMed ID: 35481313 [TBL] [Abstract][Full Text] [Related]
14. Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases. Climans SA; Macdonald DR; Sutherland DE; Mason WP BMJ Case Rep; 2020 Oct; 13(10):. PubMed ID: 33122230 [TBL] [Abstract][Full Text] [Related]
15. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis. Li Y; Song Q; Day BW Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788 [TBL] [Abstract][Full Text] [Related]
16. Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma. Asklund T; Henriksson R; Axelsson J; Bergström Å; Kasper M; Ögren M; Toftgård R; Riklund KÅ Acta Oncol; 2013 May; 52(4):862-6. PubMed ID: 23013267 [No Abstract] [Full Text] [Related]
17. MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation. Frappaz D; Barritault M; Montané L; Laigle-Donadey F; Chinot O; Le Rhun E; Bonneville-Levard A; Hottinger AF; Meyronnet D; Bidaux AS; Garin G; Pérol D Neuro Oncol; 2021 Nov; 23(11):1949-1960. PubMed ID: 33825892 [TBL] [Abstract][Full Text] [Related]
18. SHH inhibitors for the treatment of medulloblastoma. Samkari A; White J; Packer R Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634 [TBL] [Abstract][Full Text] [Related]